Justia Products Liability Opinion Summaries

Testosterone replacement drugs have been FDA-approved prescription drugs for more than 60 years. In recent years, manufacturers have found a new market: older men. Numerous lawsuits were filed against manufacturers alleging that the drugs increase health risks. Cases alleging that the manufacturers failed to warn doctors and patients adequately about the risks, citing state product-liability laws, were consolidated for pretrial proceedings. The district court granted a motion to dismiss brought by Depo-T’s manufacturer, finding the failure-to-warn claims preempted by federal law. The court stated that DepoT’s manufacturers could not change their drug labels to add warnings because FDA regulations prohibit them from “making a unilateral labeling change.” The Seventh Circuit affirmed. In Wyeth v. Levine, the Supreme Court held that claims against a manufacturer of a brand-name prescription drug for failure to warn adequately of the drug’s dangers were not preempted by federal law.; in PLIVA v. Mensing, the Court held that such failure-to-warn claims against manufacturers of generic drugs are preempted. The Court cited the different regulatory requirements and processes for approving and labeling prescription drugs. Depo-T “does not fit neatly into the colloquial dichotomy between brand-name and generic drugs” so the Seventh Circuit focused on whether the FDA approved public sale of its drugs through the “new drug application” or through the “abbreviated new drug application” (ANDA) and stated that the FDA-approved label defines an ANDA holder’s duty of sameness and the lines of federal preemption. View "Guilbeau v. Pfizer Inc." on Justia Law

Turley sued multiple defendants, alleging that he has an asbestos-related disease caused by exposure to asbestos-containing products, including valve gaskets, during his 36-year employment at PG&E. Interrogatory responses stated that Turley was exposed to asbestos-containing pipe products supplied by Familian, including “asbestos cement transite pipe, pipe collars, gaskets, elbows, pipe-repair products and other asbestos products.” Familian moved for summary judgment. arguing that plaintiffs could not show exposure to asbestos in a Familian-related product. Turley submitted a declaration from a third-party witness, Scott, who had not been deposed. The court allowed Scott to be deposed. Familian used portions of the deposition in its reply. The court concluded that the deposition testimony “conclusively negates” Scott’s declaration testimony as to exposure, refused to consider it, and granted summary judgment. The court of appeal reversed, stating that ambiguity in the evidence should be resolved at trial. Scott’s testimony established that Familian-supplied asbestos-containing gaskets were frequently used at Turley’s worksite and that Turley used them. That Familian was not the only supplier did not warrant the conclusion that Turley did not establish exposure. There was no direct contradiction between Scott’s declaration and his deposition testimony with respect to several areas, so his testimony should not have been disregarded. View "Turley v. Familian Corp." on Justia Law

Arun Gopalratnam purchased an HP laptop computer that contained a DynaPack battery pack with Samsung lithium-ion battery cells. Months later, the Menomonee Falls Fire Department responded to a major fire in a basement bedroom of the Gopalratnam’s home. After the fire was extinguished, firefighters discovered Arun deceased on the floor of the room. Am autopsy classified smoke inhalation as the cause of death, with no evidence of pre-fire injury or disease, and no drugs or alcohol in Arun’s system. Special Agent Martinez concluded that the fire originated in the basement bedroom where Arun’s body was located. Martinez excluded multiple potential sources of the blaze (electrical and gas meters, electrical distribution panels, gas-fueled furnaces, electrical plugs, light switch, and ceiling light fixture) but could not ascertain the fire’s ultimate cause. He did not eliminate a possible mattress fire. The remains of Arun’s HP laptop, cell phone, and the laptop battery cells, were in the debris. In the Gopalratnams’ suit, alleging negligence, strict products liability, and breach of warranty, the plaintiffs claimed that a defective battery cell in Arun’s laptop caused the fire. The district court granted motions to exclude plaintiffs’ expert witnesses on causation. The Seventh Circuit affirmed. The district court applied the proper legal standard: The admissibility of expert testimony is governed by Federal Rule of Evidence 702 and Daubert. The experts failed to account for other possible explanations. View "Gopalratnam v. ABC Insurance Co." on Justia Law

In June 2012, plaintiff-appellant Allen Krizhner leased a Mercedes-Benz from defendant Mercedes-Benz USA, LLC for personal use. The complaint alleged the car came with an express written warranty covering repairs for any defects. During the warranty period, the car allegedly exhibited a variety of defects which caused the navigation system and key fob to malfunction, the steering column adjustment mechanism and power seats to be inoperative, the coolant level warning light to illuminate, and smoke to emanate from the cigarette lighter. After bringing the issues to defendant’s attention, and frustrated with defendant’s supposed failure to abide by its warranty obligations, plaintiff filed suit under the Song-Beverly Consumer Warranty Act. Plaintiff accepted an offer of compromise pursuant to Code of Civil Procedure section 998, including a restitution provision identical to Civil Code section 1793.2 (d)(2)(B). The court awarded plaintiff over $47,000 in accordance with the 998 offer. Plaintiff appealed, arguing the trial court erred because it denied him recovery of approximately $680 in vehicle registration renewal and certificate of nonoperation fees which he incurred in the years after he first leased the car. The Court of Appeal concluded the court properly determined section 1793.2(b)(2)(B) did not require payment of vehicle registration renewal fees and related costs incurred after the initial purchase or lease. View "Kirzhner v. Mercedes-Benz USA, LLC" on Justia Law

In 2015, State Farm filed suit against Watts, alleging subrogated product liability claims against Watts arising from a loss that occurred in November 2012. The Court of Appeal affirmed the trial court's denial of Watt's motion to compel arbitration, finding no basis for any vested right to arbitration under the circumstances of this case, where the parties have agreed to be bound by contractual terms and rules determined by a third party. In this case, the parties signed the AF arbitration agreement some years before 2012. In 2015, the AF arbitration agreement excluded product liability claims from the kinds of claims subject to compulsory arbitration under the agreement. View "State Farm General Insurance Co. v. Watts Regulator Co." on Justia Law

The State of California prevailed in a representative public nuisance action against ConAgra, NL, and Sherwin-Williams. The trial court ordered the defendants to pay $1.15 billion into a fund to be used to abate the public nuisance created by interior residential lead paint in the ten counties represented by the state. The court of appeal affirmed in part, noting that the absence of a regulation or statute declaring interior residential lead paint to be unlawful does not bar a court from declaring it to be a public nuisance. The court reversed in part, holding that substantial evidence did not support causation as to residences built after 1950, and remanded to the trial court with directions to recalculate the amount of the abatement fund to limit it to the amount necessary to cover the cost of remediating pre-1951 homes, and hold an evidentiary hearing regarding the appointment of a suitable receiver. View "People v. ConAgra Grocery Products Co." on Justia Law

In this products liability case, the issue before the Colorado Supreme Court was whether the trial court erred when it gave a jury instruction that allowed the jury to apply either the "consumer expectation test" or the "risk-benefit test" to determine whether a driver’s car seat was unreasonably dangerous due to a design defect. The court of appeals concluded that the trial court did err by instructing the jury separately on the consumer expectation test, because the test already comprises an element of the risk-benefit test. The Supreme Court affirmed on different grounds. Previously, the Court determined the risk-benefit test was appropriate test to assess whether a product was unreasonably dangerous due to a design defect where the dangerousness of the design is “defined primarily by technical, scientific information.” The consumer expectation test, by contrast, was “not suitable” in such a case. Here, the jury was tasked with determining whether a car seat was unreasonably dangerous due to a design defect - a determination that, as evidenced by the extensive expert testimony at trial, required consideration of technical, scientific information. Thus, the Court surmised the proper test under which to assess the design’s dangerousness was the risk-benefit test, not the consumer expectation test. Therefore it was error for the trial court to instruct the jury on both tests, thereby allowing it to base its verdict on the consumer expectation test alone. Furthermore, the Court held that the jury’s separate finding of negligence did not render the instructional error harmless. View "Walker v. Ford Motor Co." on Justia Law

To seek redress for an opioid epidemic, characterized by the Court of Appeal as having placed a financial strain on state and local governments dealing with the epidemic’s health and safety consequences, two California counties sued (the California Action) various pharmaceutical manufacturers and distributors, including the appellants in this matter, Actavis, Inc., Actavis LLC, Actavis Pharma, Inc., Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc. (collectively, “Watson”). The California Action alleged Watson engaged in a “common, sophisticated, and highly deceptive marketing campaign” designed to expand the market and increase sales of opioid products by promoting them for treating long-term chronic, nonacute, and noncancer pain - a purpose for which Watson allegedly knew its opioid products were not suited. The City of Chicago brought a lawsuit in Illinois (the Chicago Action) making essentially the same allegations. The issue presented by this appeal was whether there was insurance coverage for Watson based on the allegations made in the California Action and the Chicago Action. Specifically, the issue was whether the Travelers Property Casualty Company of America (Travelers Insurance) and St. Paul Fire and Marine Insurance Company (St. Paul) owe Watson a duty to defend those lawsuits pursuant to commercial general liability (CGL) insurance policies issued to Watson. Travelers denied Watson’s demand for a defense and brought this lawsuit to obtain a declaration that Travelers had no duty to defend or indemnify. The trial court, following a bench trial based on stipulated facts, found that Travelers had no duty to defend because the injuries alleged were not the result of an accident within the meaning of the insurance policies and the claims alleged fell within a policy exclusion for the insured’s products and for warranties and representations made about those products. The California Court of Appeal concluded Travelers had no duty to defend Watson under the policies and affirmed. View "The Traveler's Property Casualty Company of America v. Actavis, Inc." on Justia Law

To seek redress for an opioid epidemic, characterized by the Court of Appeal as having placed a financial strain on state and local governments dealing with the epidemic’s health and safety consequences, two California counties sued (the California Action) various pharmaceutical manufacturers and distributors, including the appellants in this matter, Actavis, Inc., Actavis LLC, Actavis Pharma, Inc., Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc. (collectively, “Watson”). The California Action alleged Watson engaged in a “common, sophisticated, and highly deceptive marketing campaign” designed to expand the market and increase sales of opioid products by promoting them for treating long-term chronic, nonacute, and noncancer pain - a purpose for which Watson allegedly knew its opioid products were not suited. The City of Chicago brought a lawsuit in Illinois (the Chicago Action) making essentially the same allegations. The issue presented by this appeal was whether there was insurance coverage for Watson based on the allegations made in the California Action and the Chicago Action. Specifically, the issue was whether the Travelers Property Casualty Company of America (Travelers Insurance) and St. Paul Fire and Marine Insurance Company (St. Paul) owe Watson a duty to defend those lawsuits pursuant to commercial general liability (CGL) insurance policies issued to Watson. Travelers denied Watson’s demand for a defense and brought this lawsuit to obtain a declaration that Travelers had no duty to defend or indemnify. The trial court, following a bench trial based on stipulated facts, found that Travelers had no duty to defend because the injuries alleged were not the result of an accident within the meaning of the insurance policies and the claims alleged fell within a policy exclusion for the insured’s products and for warranties and representations made about those products. The California Court of Appeal concluded Travelers had no duty to defend Watson under the policies and affirmed. View "The Traveler's Property Casualty Company of America v. Actavis, Inc." on Justia Law

The Supreme Court reversed the judgment of the trial court for Plaintiff in this action brought pursuant to Connecticut’s Product Liability Act under strict liability and negligence theories, holding that Plaintiff failed to prove both that the product at issue was unreasonably dangerous and that it was a legal cause of the decedent’s fatal lung disease. In the complaint, Plaintiff alleged that the decedent was exposed to asbestos-containing products while working for Defendant and that Defendant’s actions in selling such asbestos-containing products constituted violations of the Act. After Plaintiff rested her case, Defendant moved for a directed verdict. The trial court denied Defendant’s motion as well as Defendant’s motion to set aside the verdict and for judgment notwithstanding the verdict following the jury’s verdict in Plaintiff’s favor. The Supreme Court reversed, holding that there was insufficient evidence to show that the product at issue was dangerous or that it was a legal cause of the decedent’s mesothelioma, and therefore, the trial court improperly denied Defendant’s motion for a directed verdict and motion to set aside the verdict and for judgment notwithstanding the verdict. View "Bagley v. Adel Wiggins Group" on Justia Law